Research publications

CHRU’s scientific output and contribution

Publications

CHRU Publications

Featured

Publication Date:

December 2023

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

Featured

Publication Date:

September 2023

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

Featured

Publication Date:

August 2023

Contemporary Issues in Women's Health

Featured

Publication Date:

August 2023

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

Featured

Publication Date:

August 2023

Performance of spirometry assessment at TB diagnosis

Featured

Publication Date:

July 2023

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Featured

Publication Date:

May 2023

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Featured

Publication Date:

March 2023

Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester

Featured

Publication Date:

February 2023

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Featured

Publication Date:

February 2023

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection

Featured

Publication Date:

December 2022

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Featured

Publication Date:

October 2022

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Featured

Publication Date:

October 2022

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Featured

Publication Date:

October 2022

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

Featured

Publication Date:

September 2022

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Featured

Publication Date:

September 2022

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Featured

Publication Date:

July 2022

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Featured

Publication Date:

July 2022

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

Featured

Publication Date:

May 2022

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Featured

Publication Date:

May 2022

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Featured

Publication Date:

May 2022

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Featured

Publication Date:

April 2022

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Featured

Publication Date:

April 2022

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Featured

Publication Date:

April 2022

infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Featured

Publication Date:

March 2022

Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

Featured

Publication Date:

February 2022

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral

Featured

Publication Date:

February 2022

Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19

Featured

Publication Date:

February 2022

Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste

Featured

Publication Date:

February 2022

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Featured

Publication Date:

February 2022

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled tria

Featured

Publication Date:

January 2022

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Featured

Publication Date:

December 2021

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

Featured

Publication Date:

November 2021

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Featured

Publication Date:

October 2021

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

Featured

Publication Date:

October 2021

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

Featured

Publication Date:

September 2021

Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response

Featured

Publication Date:

September 2021

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study

Featured

Publication Date:

August 2021

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

Featured

Publication Date:

July 2021

Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052

Featured

Publication Date:

July 2021

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Featured

Publication Date:

June 2021

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Featured

Publication Date:

May 2021

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

Featured

Publication Date:

May 2021

The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity

Featured

Publication Date:

April 2021

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

Featured

Publication Date:

March 2021

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Featured

Publication Date:

February 2021

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Featured

Publication Date:

January 2021

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus

Featured

Publication Date:

January 2021

Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa

Featured

Publication Date:

January 2021

Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

CHRU’s scientific output and contribution

CHRU Publications

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

Contemporary Issues in Women's Health

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

Performance of spirometry assessment at TB diagnosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral

Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19

Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled tria

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus

Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa

Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa

Year

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV

HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine: The BEe-HIVe Trial End-of-Study Results

endTB-Q results in the face of rising bedaquiline resistance

ACT 2 Clinical Trial Design: Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV

One year on - the long-term impact of COVID-19 pandemic and government restrictions on the health-seeking behaviour, financial security and mental health of TB survivors

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

Inclusion of a low- and middle-income country site in the Staphylococcus aureus Network Adaptive Platform trial: experiences from Johannesburg

Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life

Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data

DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis

Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy

Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis

Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: a Phase 2a Study in Participants at Low Risk for Acquiring HIV-1

BEAT Tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis

Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

Tuberculosis disease among people with HIV: therapeutic advances

Estimation of therapeutic threshold for tuberculosis using adapted nominal group technique and clinical vignettes in clinical and community settings in Southern Africa

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants

Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries

Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries

Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial